Abstract 6074
Background
In Spain, we do not have real-time information about cancer survivors follow-up by their family doctor. The main objective of this study is to describe the characteristics and quality of life of cancer survivors followed at a primary care center in Northwest of Spain.
Methods
An individual interview was conducted with 100 survivors of breast or colon or lung cancer, all of them free of disease five or more years after their initial diagnosis. Socio-demographic variables, care plan and global quality of life assessment (using the EORTC QLQ-C30 questionnaire), were collected.
Results
We analyzed socio-demographic data of 72 women and 28 men. At the time of the interview, their median age was 66-years-old (37-99), most were married (61%), had primary studies (58%) and do not work (77 %). We analyzed aspects related to their global quality of life by using the EORTC QLQ-C30 questionnaire. A third (36%), acknowledged that their cancer diagnosis had influenced their employment status. More than 50% of survivors recognized asthenia and/or pain at the time of the interview, and at least a 15% and 20% of these cases respectively, related these symptoms to their previous diagnosis of cancer. More than a half (56%) acknowledged their previous cancer diagnosis had changed their lifes, and to a lesser extent the life of their family (28%) and economy. A 64% of the interviewed survivors considered that their enjoyed a good or a very good quality of life. Most ot the cancer survivors (75%) described themselves as cured people.
Conclusions
Most survivors recognized that their cancer diagnosis changed their lives, and up to a third of the cases also their work situation. However, the majority of survivors report a globally good quality of life and describe themselves as cured people.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Begoña Graña.
Funding
SEOM - "Oncovida" scholarship.
Disclosure
B. Grana Suarez: Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Celgene; Research grant / Funding (institution): Roche; Travel / Accommodation / Expenses: Servier. All other authors have declared no conflicts of interest.
Resources from the same session
2477 - Antecedent of cancer and mortality after the first ST segment elevation acute myocardial infarction treated with primary coronary angioplasty. A prospective cohort study
Presenter: Irene Sillero
Session: Poster Display session 3
Resources:
Abstract
1894 - Genomic characterisation of locally advanced pancreatic adenocarcinoma
Presenter: Sarah Picardo
Session: Poster Display session 3
Resources:
Abstract
3280 - Comparison of freshly prepared and frozen cells from colorectal cancer surgical samples for phenotyping experiments- a pilot study
Presenter: Sandra Mersakova
Session: Poster Display session 3
Resources:
Abstract
3419 - Hyaluronan (HA) Accumulation in the Tumor Microenvironment (TME) is Increased in Colorectal Cancer (CRC) and Associated with Consensus Molecular Subtypes (CMS) 4 Molecular Subtype
Presenter: Barbara Blouw
Session: Poster Display session 3
Resources:
Abstract
1833 - Evaluation of CT-based radiomics in patients with renal cell carcinoma
Presenter: An Zhao
Session: Poster Display session 3
Resources:
Abstract
5883 - Detection of Double Protein Expression in Diffuse Large B Cell Lymphoma
Presenter: Mohamed Gouda
Session: Poster Display session 3
Resources:
Abstract
5415 - Encyclopedic Tumor Analysis for organ agnostic treatment with Axitinib in combination regimens for advanced cancers
Presenter: Tim Crook
Session: Poster Display session 3
Resources:
Abstract
3297 - Computational model to predict response rate of clinical trials
Presenter: Orsolya Lorincz
Session: Poster Display session 3
Resources:
Abstract
4355 - Analysis of BRCA genes and homologous recombination deficiency (HRD) scores in tumours from patients (pts) with metastatic breast cancer (mBC) in the OlympiAD trial
Presenter: Mark Robson
Session: Poster Display session 3
Resources:
Abstract
2316 - A 3D co-culture platform of breast cancer and patient derived immune cells to analyse the response to chemotherapy and immunotherapies
Presenter: Diana Saraiva
Session: Poster Display session 3
Resources:
Abstract